Industry Overview - The functional skincare market has become a dominant segment within the broader skincare industry, driven by increasing consumer awareness of skin issues and ingredient research [3][5] - Functional skincare products are designed for individuals with specific skin concerns, including whitening, anti-aging, sun protection, and hydration, often containing medicinal ingredients [1][5] Market Growth - The global functional skincare market is projected to grow from $35.3 billion in 2016 to $168 billion by 2024, while the Chinese market is expected to increase from 7.42 billion yuan to 48 billion yuan in the same period [5] - The demand for functional skincare products is fueled by the rise of ingredient-conscious consumers, sensitive skin populations, and post-aesthetic treatment recovery needs [3][5] Product Categories - Functional skincare products encompass three main categories: dermatological skincare, efficacy-driven skincare, and medical-grade skincare, with "pharmaceutical cosmetics" falling under dermatological skincare [5] - Professional skincare products are further divided into patch-based and non-patch-based forms, with patch-based products, such as masks, projected to grow from 2.38 billion yuan in 2017 to 19.34 billion yuan by 2024 [5] Industry Leaders - Companies like Huaxi Biological, Beitaini, and Juzhi Biological are recognized as industry leaders, driving development through innovation [9] Consumer Trends - The evolution of functional skincare reflects a dual pursuit of beauty and health, highlighting a growing consumer awareness of personal skincare needs [11]

一直在路上，所以停下脚步，只在于分享 包括： 新 材料/ 半导体 / 新能源/光伏/显示材料 等 添加 小编微信 ，遇见 志同道合 的你 写在前面 （文末有惊喜） 正文 = 在 1 is fo 基础化工 点击 最 下方 "在看"和" "并分享，"关注"材料汇 行业专题 以生物造万物. 构建 Al+新质生产力新业态 合成生物深度系列报告之一 主要观点: ● 合成生物学是生产力转型升级新方向 合成生物学是一门基于工程化的设计理念,结合生物学、化学、医 学、农学、工程学、计算机与数据科学等交叉学科技术,旨在设计 和构建新的生物系统,以实现特定的功能,其本质是让细胞为人类 工作生产想要的物质。合成生物学和发酵工程的区别在于是否对细 胞进行定向性干预,大幅提升微生物细胞工厂效率。目前合成生物 学可合成的大宗化学品仅几十种,在整体基础化学品中的占比还非 常有限,还无法颠覆性替代传统化工,但在部分领域有比较好的应 用场景,具有战略与商业角度的优势,生物制造未来提升空间巨 大。 ● Al 赋能上游+政策推动落地,合成生物学东风将至 当前,国际合成生物学优势力量主要分布在美、欧等地,其政策对 我国来说具备一定参考意义,国内也正 ...

或许你已经发现，走进家里小区楼下的药店，第一眼看到的可能不是药品，而是薇诺娜、可复 美、绽妍等品牌的护肤产品，这一幕正悄然成为中国药店的"新常态"。 近日，福瑞达生物公布了年内覆盖1 0个千万级OTC连锁的大计划。无独有偶，百雀羚也于年 初宣布正式入驻北京同仁堂渠道。随着线上红利逐渐见顶，不少品牌开始瞄准线下OTC专业渠 道掘金。 《FBe a u t y未来迹》经过调研发现，美妆在OTC渠道的生意，比起未开发的蓝海，更像是一支 蓄势待发的弓箭。在已经跑出薇诺娜这个十亿级销售规模美妆品牌的情况下，依旧还有巨大的 想象空间。 OTC渠道可以说是目前在线下分布最广的一类渠道，正如居民楼附近不一定会有化妆品店，但 一定会有药店，而这不是错觉。 根据薇诺娜母公司贝泰妮集团发布的2 0 2 4年上半年财报，OTC分销渠道销售模式实现营业收 入人民币3 5 , 4 7 0 . 1 4万元，约占主营业务收入1 2 . 7 1%，同比增长约2 0 . 0 1%。 按照这一增速， 薇诺娜在OTC的年销售规模大概率已经迈过1 0亿门槛。 据公开资料，薇诺娜从2 0 1 6年开始与连锁药房合作，彼时市场体量只有5 0万左右；8年后 ...

Core Insights - The AI Fund Guangfa Hong Kong and Shenzhen New Opportunities Stock (001764) reported a profit of 42.15 million yuan for Q1 2025, with a weighted average profit per fund share of 0.0675 yuan. The fund's net value growth rate was 7.97%, and the fund size reached 637 million yuan by the end of Q1 2025 [2][15]. Fund Performance - As of April 18, the fund's unit net value was 1.028 yuan. The fund manager, Li Yaozhu, oversees nine funds, with the Guangfa Hong Kong Stock Connect Growth Selected Stock A achieving the highest one-year return of 15.32%, while Guangfa Ju You Flexible Allocation Mixed A recorded the lowest at -7.17% [2][3]. Investment Strategy - The fund's management emphasized a focus on China's new consumption sector, particularly in Hong Kong stocks. The shift in consumer behavior towards quality of life and spiritual needs is expected to create new consumption giants. The fund aims to identify companies with brand advantages that provide high-quality products, particularly those reflecting Chinese cultural elements in sectors like trendy toys, luxury goods, tea drinks, cosmetics, and medical beauty [3]. Comparative Performance - As of April 18, the fund's performance metrics include a three-month net value growth rate of 6.87%, ranking 7 out of 74 comparable funds; a six-month growth rate of -6.79%, ranking 60 out of 74; a one-year growth rate of 9.37%, ranking 28 out of 74; and a three-year growth rate of -7.72%, ranking 40 out of 73 [3]. Risk Metrics - The fund's Sharpe ratio over the past three years was 0.3336, ranking 32 out of 73 comparable funds. The maximum drawdown over the same period was 43.41%, with the largest single-quarter drawdown occurring in Q1 2022 at 30.1% [8][10]. Investment Concentration - The fund has a high concentration in its holdings, with the top ten stocks consistently representing over 60% of the portfolio for nearly two years. As of Q1 2025, the top ten holdings included Tencent Holdings, Xiaomi Group-W, Alibaba-W, Pop Mart, Lao Pu Gold, BYD Co., Mao Ge Ping, Juzi Biology, TCL Electronics, and Ninebot [19].

Core Viewpoint - The controversy surrounding the skincare brand Kefu Mei, owned by Giant Bio (02367.HK), involves allegations of containing the banned ingredient EGF (Epidermal Growth Factor), leading to consumer complaints and regulatory scrutiny [2][3][6]. Company Overview - Giant Bio was established in 2000 and went public on the Hong Kong Stock Exchange in 2022. The company owns multiple brands, including Kefu Mei, Keli Jin, and Xin Gan [6]. - In 2024, the company reported a revenue increase of 57.2% to 5.539 billion yuan, with a net profit growth of 42.1% to 2.062 billion yuan. The gross margin decreased from 83.6% in 2023 to 82.1% [6]. Regulatory Actions - The Shaanxi Provincial Drug Administration conducted inspections in March and April 2024 and found no evidence of EGF being added during the production process, leading to a decision not to file a case [2][3]. - A follow-up inspection in April 2025 also did not reveal any violations regarding the addition of EGF. The agency employed liquid chromatography-mass spectrometry (LC-MS) for testing multiple batches of the product, which also did not detect EGF [3]. Product Safety and Compliance - The National Medical Products Administration stated in 2019 that EGF cannot be used as a cosmetic ingredient, and any product claiming to contain EGF is considered illegal. EGF is primarily used in medical fields for treating burns and wounds [6]. - The controversy began when a consumer reported adverse effects after using Kefu Mei's "Recombinant Collagen Repair Dressing (G-type)" and later found EGF in the product through independent testing [2].

Core Insights - On April 17, 2023, Juzibio made its debut on the Hong Kong Stock Connect active trading list for the first time in a month [2][3] - The total trading volume of active stocks on the Hong Kong Stock Connect reached HKD 382.32 billion, accounting for 42.41% of the day's total trading volume, with a net buying amount of HKD 5.99 billion [2] - Alibaba-W led the trading volume with HKD 65.85 billion, followed by Tencent Holdings and Xiaomi Group-W with HKD 59.17 billion and HKD 57.81 billion, respectively [2] Trading Activity Summary - The active stocks on April 17 included: - Tencent Holdings: Trading volume of HKD 59.17 billion, net buying of HKD 7.82 billion, and a closing price of HKD 458.00 with a daily increase of 2.23% [2] - Alibaba-W: Trading volume of HKD 65.85 billion, net buying of HKD 8.35 billion, and a closing price of HKD 108.70 with a daily increase of 3.13% [2] - Xiaomi Group-W: Trading volume of HKD 57.81 billion, net selling of HKD 13.43 billion, and a closing price of HKD 41.95 with a daily increase of 1.70% [2] - Juzibio: Trading volume of HKD 6.35 billion, net buying of HKD 4.16 billion, and a closing price of HKD 72.10 with a daily decrease of 2.10% [3] Recent Performance - Over the past month, Alibaba-W, Tencent Holdings, and Xiaomi Group-W have been the most frequently listed stocks on the active trading list, each appearing 22 times [2] - Juzibio's recent trading activity indicates a growing interest, as it was the only stock to debut on the active list on April 17 [2][3]

Group 1: Market Overview - Northbound trading recorded a net buy of HKD 23.09 billion, with HK Stock Connect (Shanghai) contributing HKD 5.08 billion and HK Stock Connect (Shenzhen) contributing HKD 18.01 billion [1] - The most net bought stocks included Alibaba-W (09988), Tencent (00700), and Meituan-W (03690) [1][4] - The most net sold stocks were Yingfu Fund (02800), Xiaomi Group-W (01810), and CNOOC (00883) [1] Group 2: Stock Performance - Alibaba-W saw a net inflow of HKD 3.11 billion, with total trading volume of HKD 41.78 billion [2] - Xiaomi Group-W experienced a net outflow of HKD 6.15 billion, with total trading volume of HKD 35.74 billion [2] - Tencent recorded a net inflow of HKD 819.94 million, with total trading volume of HKD 31.70 billion [2] Group 3: Sector Insights - Morgan Stanley's report indicates that the impact of the US-China trade war on Chinese internet companies is mostly indirect, with an estimated effect on online consumption being less than 0.5% [4] - HSBC's research suggests that while the Chinese internet sector may experience volatility due to trade tensions, the direct impact from tariff policies is limited [4] Group 4: Company-Specific Developments - Giant Bio (02367) received a net buy of HKD 4.16 billion, planning to raise approximately HKD 22.94 billion through a discounted share placement for business development and working capital [5] - Pop Mart (09992) saw a net buy of HKD 2.27 billion, with a focus on global organizational restructuring to enhance its international strategy [5] - Xiaomi Group-W's recent financing plans include a HKD 425 billion share placement and a HKD 200 billion bond project, leading to significant net selling [7] Group 5: Commodity and Semiconductor Sector - Semiconductor stocks like Hua Hong Semiconductor (01347) and SMIC (00981) received net buys of HKD 1.97 billion and HKD 615 million respectively, amid favorable domestic policies [6] - The price of gold has reached a historical high of USD 3,350 per ounce, benefiting companies like Chifeng Jilong Gold Mining (06693) which saw a net buy of HKD 1.82 billion [6]

Group 1 - The company plans to raise approximately HKD 23.33 billion by placing 35 million existing shares at a price of HKD 66.65 per share, with a net amount of about HKD 22.94 billion expected after expenses [1] - The placement price represents a discount of 9.5% to the closing price prior to the announcement and a 6.78% discount to the average price over the past five days [1] - This is the second equity financing since the company's IPO, with total fundraising now nearing HKD 40 billion, significantly higher than the initial IPO amount of HKD 5.49 billion [1] Group 2 - In 2024, the company achieved revenue of approximately HKD 55.39 billion, a year-on-year increase of about 57%, and a net profit of approximately HKD 20.62 billion, up 42% year-on-year [2] - The gross profit margin stands at 82.1%, with the main product line, 可复美, generating sales of HKD 45.42 billion, a 62.9% increase, and accounting for 82.0% of total revenue [2] - The company faces challenges such as low R&D investment, which was only HKD 1.06 billion (1.9% of revenue) in 2024, compared to competitors with significantly higher R&D expense ratios [2]

Core Viewpoint - The company, Juzi Bio (02367.HK), has entered into a placement and subscription agreement to sell and issue shares at a price of HKD 66.65 per share, aiming to raise approximately HKD 23.33 billion for business development and general corporate purposes [1][2]. Group 1 - The seller has agreed to sell 35 million shares, which represents about 3.38% of the company's issued shares as of the announcement date [1]. - The total expected net proceeds from the placement and subscription are approximately HKD 22.94 billion, which will be used for core business development, marketing, and R&D investments [1]. - The placement is expected to enhance the company's financial strength, market competitiveness, and overall capabilities, promoting long-term sustainable development [2]. Group 2 - The placement will attract high-quality institutional investors, enriching the company's shareholder base and improving share liquidity [2]. - The subscription shares will be issued under general authorization, ensuring compliance with regulatory requirements [2].

Group 1 - The company, Giant Bio (02367), announced a placement and subscription agreement on April 16, 2025, where the seller agreed to sell 35 million shares at a price of HKD 66.65 per share [1] - The placement price of HKD 66.65 represents a discount of approximately 9.50% compared to the closing price of HKD 73.65 on April 16, 2025 [1] - The total amount expected from the placement and subscription is approximately HKD 2.333 billion, with a net amount of about HKD 2.294 billion after deducting commissions and estimated expenses [1] Group 2 - The net proceeds from the placement and subscription are intended for core business development and ecosystem layout, including brand promotion, marketing, category expansion, overseas business, R&D investment, and general corporate purposes [1] - The announcement states that the fundraising will enhance the company's financial strength, market competitiveness, and overall capabilities, promoting long-term healthy and sustainable development [1] - The placement is expected to attract high-quality institutional investors, enriching the company's shareholder base and improving share liquidity [1] Group 3 - The seller is a limited liability company registered under the laws of the British Virgin Islands, holding approximately 56.10% of the company's existing issued share capital [2] - The seller acts as a holding vehicle for the FY Family Trust, with the spouse of executive director Yan Jianya serving as the trustee and beneficiary [2]